Navigation Links
Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 September 2009
Date:11/11/2009

Bavarian Nordic expects that an end of phase II meeting with the FDA will take place during January 2010. While partnership negotiations are ongoing, the company is in preparations for Phase III and these are proceeding as planned.

Lately, the prostate cancer field has witnessed positive clinical results followed by attractive partnership deals. It has proven worthwhile for a number of companies to independently advance their projects into Phase III, thus maximising their value before they would eventually sign a licensing deal. Similarly, Bavarian Nordic is seeking to maximise and retain the value of its cancer portfolio. Consequently, Bavarian Nordic seeks the ability to advance PROSTVAC(TM) into Phase III of its own. In order for Bavarian Nordic to gain the independence to execute its short and long term activities within biodefence and cancer, the company is exploring available options for securing an optimum financial position.

Highlights from the period

Bavarian Nordic has signed contract with an EU country for the delivery of IMVAMUNE(R)

In September, Bavarian Nordic signed a contract with the military of an undisclosed EU country for the delivery of a small order for IMVAMUNE(R). The size and value of the contract is undisclosed. This marks the first time, Bavarian Nordic enters a contract with an EU country for the delivery of IMVAMUNE(R), and it demonstrates that there exists a real demand inside of EU for new and safer smallpox vaccines for preparedness stockpiles. The vaccines have been delivered.

Negotiations with the US authorities for the further development of IMVAMUNE(R)

Bavarian Nordic is currently in late-stage negotiations with the US authorities for a new contract to develop a freeze-dried version of the IMVAMUNE(R) smallpox vaccine. This potential new project will have no influence on the ongoing RFP-3 contract for the procurement of 20 million doses of IMVAMUNE(R) and the
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Bavarian Nordic Has Signed Contract With an EU Country for the Delivery of IMVAMUNE(R)
2. Bavarian Nordic A/S - Half Year Interim Report 2009
3. Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE(R)
4. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
5. Bavarian Nordic Announces its Interim Report for the Period 1 January to 31 March 2009
6. Bavarian Nordic Publishes its Annual Results 2008
7. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
8. Bavarian Nordics Case Against Oxford BioMedica
9. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
10. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
11. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Vital Imaging ™ has teamed ... San Diego for a joint study which aims to ... Resonance Imaging) with that of a supine Dynawell MRI ... of improved healthcare by combining cutting edge technology with ... valuable tool for evaluating pathological changes in the spine, ...
(Date:5/21/2013)... 21, 2013 PathoGenetix, Inc., a commercial-stage ... typing, announced today that it has successfully identified and ... strains obtained from the Centers for Disease Control and ... technology. The findings are detailed in a poster ... Society for Microbiology in Denver on Monday. , The ...
(Date:5/20/2013)... , Collaboration with the ... in treatment of mastitis , ... to begin in the second half 2013 ... Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) will collaborate ... Service (ARS) to develop and trial products targeting the ...
(Date:5/20/2013)... 2013  MiMedx Group, Inc. (NASDAQ: MDXG ... protected regenerative biomaterials and bioimplants processed from human amniotic ... line of credit with Bank of America.  The revolving ... Company,s accounts receivable and inventory, allows MiMedx to borrow ... facility will be used for general corporate purposes. ...
Breaking Biology Technology:Vital Imaging Makes Greater Commitment into MRI Research 2Vital Imaging Makes Greater Commitment into MRI Research 3New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3Phosphagenics Signs Research Agreement with the Agricultural Research Service 2
... now have a new tool to help diagnose symptomatic patients ... the most common sexually transmitted infections in the world.   ... and Company), announced today that it received U.S. Food and ... molecular tests to detect and differentiate HSV types 1 and ...
... BioTechnologies, Inc. (TriLink) announced that it has entered into ... its CleanAmp™ Products. The Scandinavian based TATAA develops and ... in addition to providing tailor-made products for real-time PCR ... Hot Start PCR, TriLink,s CleanAmp™ Product Line is an ...
... Inc. (OTC Bulletin Board: BONU ), a ... of Dr. Stephen Holt, M.D., Ph.D, a Distinguished Professor ... York State, as the Company,s Vice Chairman of the ... consultant to the pharmaceutical and dietary supplement industry, and ...
Cached Biology Technology:BD Diagnostics Receives FDA Clearance for First Fully Automated Molecular Assays for HSV1 and HSV2 from Clinician-Collected External Anogenital Lesion Specimens 2TriLink Enters Into Distribution Agreement With TATAA Biocenter 2BioNeutral Elects Stephen Holt, M.D., Ph.D as Vice Chairman and Independent Director of the Board 2BioNeutral Elects Stephen Holt, M.D., Ph.D as Vice Chairman and Independent Director of the Board 3
(Date:5/18/2013)... MD (May 19, 2013) The AGA Research Foundation ... and Damian Augustyn Award in Digestive Cancer, which will ... of Medicine at the University of Pennsylvania, Philadelphia, as ... in pancreas development, regeneration and cancer progression. , "The ... in honor of two distinguished clinicians and AGA Legacy ...
(Date:5/18/2013)... Research presented at Digestive Disease Week (DDW) explores ... and lifestyle. , Individuals suffering from Crohn,s ... fatigue and poor quality of life. These symptoms ... A randomized, double blind, placebo-controlled study found for ... to significant relief of these symptoms. , ...
(Date:5/17/2013)... 2013) The AGA Research Foundation announced a new ... between the gut microbiota, one of today,s most exciting ... , The AGA Research Awards Panel selected Andrew T. ... Hospital and Harvard Medical School, Boston, as the 2013 ... will receive $25,000 of funding, commencing in July 2013, ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3New gut microbiome research to explore red meat -- colorectal cancer pathway 2
... with the hepatitis C virus (HCV) are at an ... lymphatic system), according to a study published in the ... American Medical Association. Researchers from the National Cancer ... and Baylor College of Medicine, found that HCV infection ...
... greatest importance nowadays since it express who we are, but is ... its form? The answer to that question seems to be related ... Universidad Nacional Autonoma de Mexico and the Buck Institute in the ... than fashion. , In biology, the capacity to establish the ...
... Jake Najman and Gail Williams and Stockholm University's Professor Robin ... between 1981 and 2002. , Their results were published ... and Alcohol Review. , The men were categorised ... worker status is a marker for lower socio-economic status (SES). ...
Cached Biology News:Risk of lymphoma increases with hepatitis C virus infection 2Double the death rate from cirrhosis for 'blue collar' men 2
96-well format (For processing samples on microplate-size MALDI target plates such as those from Bruker, Shimadzu, Thermo, and PerkinElmer) Packaging: 2 / pack...
... recombinant IFNA2. Immunogen: Human IFNA2 ... in E. coli. The biological activity was ... OMIM: 147562, GeneID: ... MA Code: ABV0P9DPB ...
Mouse monoclonal antibody raised against a partial recombinant CENTB2. NCBI Entrez Gene ID = CENTB2...
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
Biology Products: